Haring-Layton MarDee 4

What Happened MarDee Haring-Layton, Chief Accounting Officer of Dare Bioscience (DARE), received a grant of 49,000 derivative shares (stock-option award) on January 30, 2026. The reported acquisition price is $0.00 (the award was granted, not purchased), so there was no cash outlay recorded by the insider at grant.

Key Details

• Transaction date: 2026-01-30; filing date: 2026-02-02 (Form 4 accession 0001535596-26-000002).
• Amount: 49,000 derivative securities (stock-option award); reported price: $0.00.
• Vesting: 48 equal monthly installments beginning one month after the grant date, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided summary of the filing.
• No sale or exercise occurred — this is an award/grant of derivative securities.

Context This was a compensatory award of derivative securities (stock options) to an executive, which typically vests over time and does not represent an immediate market buy or sell. Because the award vests monthly over four years, its value to the insider is tied to continued service and future company performance; the filing shows no immediate cash transaction.